Alnylam Pharmaceuticals
ALNY
#600
Rank
A$57.90 B
Marketcap
A$433.97
Share price
0.70%
Change (1 day)
16.68%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2025 (TTM): A$2.66

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is A$2.52. In 2023 the company made an earnings per share (EPS) of A-$4.93 an increase over its 2022 EPS that were of A-$12.98.

EPS history for Alnylam Pharmaceuticals from 2012 to 2025

Annual EPS

Year EPS Change
2025 (TTM)A$2.66
2023A-$4.93-62%
2022A-$12.9829.03%
2021A-$10.06-3.36%
2020A-$10.41-8.48%
2019A-$11.377.67%
2018A-$10.5639.74%
2017A-$7.5612.94%
2016A-$6.6938.84%
2015A-$4.82-32.88%
2014A-$7.18259.44%
2013A-$2.00-31.25%
2012A-$2.91

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Novartis
NVS
A$10.06 300.00%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
A$2.89 14.73%๐Ÿ‡ซ๐Ÿ‡ท France
Regeneron Pharmaceuticals
REGN
A$60.25 2,295.56%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
A-$3.83-252.22%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
A-$1.02-140.56%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
A-$0.34-113.33%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
A$1.73-31.11%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Arrowhead Pharmaceuticals
ARWR
A$0.49-80.56%๐Ÿ‡บ๐Ÿ‡ธ USA